Communiqués Alaunos Therapeutics, Inc.

Actions

TCRT

US98973P2002

Temps réel estimé Cboe BZX Autres places de cotation 19:12:47 17/07/2024			Varia. 5j.	Varia. 1 janv.
0,586 ^USD	-4,70 %		-2,02 %	-44,56 %

10/06	BioSig Technologies nomme Ferdinand Groenewald directeur financier par intérim	MT
15/05	Alaunos Therapeutics, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Ziopharm: Q1 Earnings Snapshot	15/05	AQ
Ziopharm: Q3 Earnings Snapshot	14/11	AQ
Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives	14/11	AQ
Ziopharm: Q2 Earnings Snapshot	14/08/23	AQ
Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic Alternatives	14/08/23	AQ
Alaunos Therapeutics Announces Presentation at the 2nd Hawaii Global Summit on Thoracic Malignancies	29/06/23	AQ
ALAUNOS THERAPEUTICS, INC. : Material Modification to Rights of Security Holders, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)	12/06/23	AQ
Alaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/2 Trial at 2023 American Society of Clinical Oncology Annual Meeting	25/05/23	AQ
Ziopharm: Q1 Earnings Snapshot	10/05/23	AQ
ALAUNOS THERAPEUTICS, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)	10/05/23	AQ
Alaunos Therapeutics Reports First Quarter 2023 Financial Results	10/05/23	AQ
Alaunos Therapeutics to Report First Quarter 2023 Financial Results on May 10, 2023	03/05/23	AQ
Alaunos Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting	26/04/23	AQ
ALAUNOS THERAPEUTICS, INC. : Entry into a Material Definitive Agreement (form 8-K)	03/04/23	AQ
ALAUNOS THERAPEUTICS, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	30/03/23	AQ
Alaunos Therapeutics Appoints Dr. Robert J. Hofmeister to Board of Directors	30/03/23	AQ
Alaunos Therapeutics to Participate in Upcoming Investor Conferences in April	29/03/23	AQ
Ziopharm: Q4 Earnings Snapshot	07/03/23	AQ
ALAUNOS THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	07/03/23	AQ
ALAUNOS THERAPEUTICS, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)	07/03/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Alaunos Therapeutics, Inc.

Actions

TCRT

US98973P2002

Communiqués

Filtres